TACC3 and neoplasm: Furthermore, a phase I trial (NCT01962532) using JNJ-42756493 to treat two patients with recurrent GBM harboring FGFR3-TACC3 fusions resulted in clinical improvements: one in disease stability; another has shown reduction of tumor size.